Plasma Amyloid-β Peptides in Type 2 Diabetes: A Matched Case-Control Study

Journal of Alzheimer's Disease

Volumn 56, Issue 3, 2017, Pages 1127-1133

  Peters, Kirsten E ^a   Davis, Wendy A ^a   Taddei, Kevin ^b,c   Martins, Ralph N ^b   Masters, Colin L ^d   Davis, Timothy M E ^a   Bruce, David G ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b EDITH COWAN UNIVERSITY   (Australia)

^c MACQUARIE UNIVERSITY   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Alzheimer's disease; amyloid ; blood biomarkers; peptides; type 2 diabetes mellitus

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); APOLIPOPROTEIN E4; BIOLOGICAL MARKER; PEPTIDE FRAGMENT;

AGED; ALLELE; ARTICLE; CASE CONTROL STUDY; COGNITION; COHORT ANALYSIS; CONTROLLED STUDY; DIABETIC PATIENT; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; HUMAN; IMMUNOASSAY; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; BLOOD; CLINICAL TRIAL; GENETICS; LONGITUDINAL STUDY; PHASE 2 CLINICAL TRIAL;

AGED; AMYLOID BETA-PEPTIDES; APOLIPOPROTEIN E4; BIOMARKERS; CASE-CONTROL STUDIES; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; PEPTIDE FRAGMENTS;

EID: 85011579342     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-161050     Document Type: Article

References (29)

1. Exalto LG, Whitmer RA, Kappele LJ, Biessels GJ (2012) An update on type 2 diabetes, vascular dementia and Alzheimer's disease. Exp Gerontol 47, 858-864
2. Cheng G, Huang C, Deng H, Wang H (2012) Diabetes as a risk factor for dementia and mild cognitive impairment: A meta-analysis of longitudinal studies. Intern Med J 42, 484-491
3. Gudala K, Bansal D, Schifano F, Bhansali A (2013) Diabetes mellitus and risk of dementia: A meta-analysis of prospective observational studies. J Diabetes Investig 4, 640-650
4. Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P (2006) Risk of dementia in diabetes mellitus: A systematic review. Lancet Neurol 5, 64-74
5. Li L, Holscher C (2007) Common pathological processes in Alzheimer disease and type 2 diabetes: A review. Brain Res Rev 56, 384-402
6. Koyama A, Okereke OI, Yang T, Blacker D, Selkoe DJ, Grodstein F (2012) Plasma amyloid-beta as a predictor of dementia and cognitive decline: A systematic review and meta-analysis. Arch Neurol 69, 824-831
7. Toledo JB, Vanderstichele H, Figurski M, Aisen PS, Petersen RC, Weiner MW, Jack CR Jr, Jagust W, Decarli C, Toga AW, Toledo E, Xie SX, Lee VM, Trojanowski JQ, Shaw LM, Alzheimer's Disease Neuroimaging, Initiative (2011) Factors affecting Abeta plasma levels and their utility as biomarkers in ADNI. Acta Neuropathol 122, 401-413
8. Chouraki V, Beiser A, Younkin L, Preis SR, Weinstein G, Hansson O, Skoog I, Lambert JC, Au R, Launer L, Wolf PA, Younkin S, Seshadri S (2015) Plasma amyloid-beta and risk of Alzheimer's disease in the Framingham Heart Study. Alzheimers Dement 11, 249-257
9. Rembach A, Faux NG, Watt AD, Pertile KK, Rumble RL, Trounson BO, Fowler CJ, Roberts BR, Perez KA, Li QX, Laws SM, Taddei K, Rainey-Smith S, Robertson JS, Vandijck M, Vanderstichele H, Barnham KJ, Ellis KA, Szoeke C, Macaulay L, Rowe CC, Villemagne VL, Ames D, Martins RN, Bush AI, Masters CL, research AIBL, group (2014) Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease. Alzheimers Dement 10, 53-61
10. Zhang Y, Zhou B, Zhang F, Wu J, Hu Y, Liu Y, Zhai Q (2012) Amyloid-beta induces hepatic insulin resistance by activating JAK2/STAT3/SOCS-1 signaling pathway. Diabetes 61, 1434-1443
11. Blasko I, Jungwirth S, Jellinger K, Kemmler G, Krampla W, Weissgram S, Wichart I, Tragl KH, Hinterhuber H, Fischer P (2008) Effects of medications on plasma amyloid beta (Abeta) 42: Longitudinal data from the VITA cohort. J Psychiatr Res 42, 946-955
12. Balakrishnan K, Verdile G, Mehta PD, Beilby J, Nolan D, Galvao DA, Newton R, Gandy SE, Martins RN (2005) Plasma Abeta42 correlates positively with increased body fat in healthy individuals. J Alzheimers Dis 8, 269-282
13. Davis TM, Bruce DG, Davis WA (2013) Cohort profile: The Fremantle Diabetes Study. Int J Epidemiol 42, 412-421
14. Ellis KA, Bush AI, Darby D, De Fazio D, Foster J, Hudson P, Lautenschlager NT, Lenzo N, Martins RN, Maruff P, Masters C, Milner A, Pike K, Rowe C, Savage G, Szoeke C, Taddei K, Villemagne V, Woodward M, Ames D (2009) The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: Methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. Int Psychogeriatr 21, 672-687
15. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130, 461-470
16. Levey AS, de Jong PE, Coresh J, El Nahas M, Astor BC, Matsushita K, Gansevoort RT, Kasiske BL, Eckardt KU (2011) The definition, classification, and prognosis of chronic kidney disease: A KDIGO Controversies Conference report. Kidney Int 80, 17-28
17. Norman PE, Davis WA, Bruce DG, Davis TM (2006) Peripheral arterial disease and risk of cardiac death in type 2 diabetes: The Fremantle Diabetes Study. Diabetes Care 29, 575-580
18. Bates KA, Verdile G, Li QX, Ames D, Hudson P, Masters CL, Martins RN (2009) Clearance mechanisms of Alzheimer's amyloid-beta peptide: Implications for therapeutic design and diagnostic tests. Mol Psychiatry 14, 469-486
19. Liu YH, Xiang Y, Wang YR, Jiao SS, Wang QH, Bu XL, Zhu C, Yao XQ, Giunta B, Tan J, Zhou HD, Wang YJ (2015) Association between serum amyloid-beta and renal functions: Implications for roles of kidney in amyloid-beta clearance. Mol Neurobiol 52, 115-119.
20. Arvanitakis Z, Lucas JA, Younkin LH, Younkin SG, Graff-Radford NR (2002) Serum creatinine levels correlate with plasma amyloid beta protein. Alzheimer Dis Assoc Disord 16, 187-190
21. Gronewold J, Klafki HW, Baldelli E, Kaltwasser B, Seidel UK, Todica O, Volsek M, Haussmann U, Wiltfang J, Kribben A, Bruck H, Hermann DM (2016) Factors responsible for plasma beta-amyloid accumulation in chronic kidney disease. Mol Neurobiol 53, 3136-3145
22. Jerums G, Premaratne E, Panagiotopoulos S, MacIsaac RJ (2010) The clinical significance of hyperfiltration in diabetes. Diabetologia 53, 2093-2104
23. Helal I, Fick-Brosnahan GM, Reed-Gitomer B, Schrier RW (2012) Glomerular hyperfiltration: Definitions, mechanisms and clinical implications. Nat Rev Nephrol 8, 293-300
24. Narita T, Sasaki H, Hosoba M, Miura T, Yoshioka N, Morii T, Shimotomai T, Koshimura J, Fujita H, Kakei M, Ito S (2004) Parallel increase in urinary excretion rates of immunoglobulin G, ceruloplasmin, transferrin, and orosomucoid in normoalbuminuric type 2 diabetic patients. Diabetes Care 27, 1176-1181
25. Xiang Y, Bu XL, Liu YH, Zhu C, Shen LL, Jiao SS, Zhu XY, Giunta B, Tan J, Song WH, Zhou HD, Zhou XF, Wang YJ (2015) Physiological amyloid-beta clearance in the periphery and its therapeutic potential for Alzheimer's disease. Acta Neuropathol 130, 487-499
26. Liu YH, Wang YR, Xiang Y, Zhou HD, Giunta B, Manucat-Tan NB, Tan J, Zhou XF, Wang YJ (2015) Clearance of amyloid-beta in Alzheimer's disease: Shifting the action site from center to periphery. Mol Neurobiol 51, 1-7
27. Moran C, Beare R, Phan TG, Bruce DG, Callisaya ML, Srikanth V (2015) Type 2 diabetes mellitus and biomarkers of neurodegeneration. Neurology 85, 1123-1130
28. Abner EL, Nelson PT, Kryscio RJ, Schmitt FA, Fardo DW, Woltjer RL, Cairns NJ, Yu L, Dodge HH, Xiong C, Masaki K, Tyas SL, Bennett DA, Schneider JA, Arvanitakis Z (2016) Diabetes is associated with cerebrovascular but not Alzheimer's disease neuropathology. Alzheimers Dement 12, 882-889
29. Willette AA, Johnson SC, Birdsill AC, Sager MA, Christian B, Baker LD, Craft S, Oh J, Statz E, Hermann BP, Jonaitis EM, Koscik RL, La Rue A, Asthana S, Bendlin BB (2015) Insulin resistance predicts brain amyloid deposition in late middle-aged adults. Alzheimers Dement 11, 504-510. e501